Another Fatal Case of Hyperphosphatemia Associated with a Phosphosoda Bowel Preparation;Intravenous Immune Globulin Causes Myocardial Infarction;Hepatotoxicity Due to Acarbose Therapy;Mitochondrial Toxicity with Linezolid;Venlafaxine and the Rapid Development of Anasarca;Neuropathy Exacerbated by Rituximab Therapy;Drug-Related Emergency Department Visits in an Elderly Population;House Staff Report on Adverse Events and Their Causes

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers. Write to Dr. Shuster at ISMP, 1800 Byberry Road, Suite 810, Huntingdon Valley, PA 19006 (call 215-947-7797; fax 215-914-1492; E-mail joel.shuster@temple.edu). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices in cooperation with the FDA's medWatch Program and Temple University School of Pharmacy. ISMP is an FDA medWatch partner.